Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 4—April 2024
Dispatch

Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022

Farrell A. TobolowskyComments to Author , Fred Nsubuga, Zunera Gilani, Annet Kisakye, Helen Ndagije, Daniel Kyabayinze, and Jane F. Gidudu
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (F.A. Tobolowsky, Z. Gilani, J.F. Gidudu); African Field Epidemiology Network, Kampala, Uganda (F. Nsubuga); Uganda National Expanded Program on Immunizations, Kampala (F. Nsubuga, D. Kyabayinze); World Health Organization, Kampala (A. Kisakye); National Drug Authority, Kampala (H. Ndagije)

Main Article

Table

Adverse events identified by all surveillance systems after nOPV2 administration, Uganda, 2022*

​Event Total Minor AEFI† Serious​ AEFI
​Passive surveillance 43 41 2
​​Acute flaccid paralysis surveillance 159‡ 78§ 81
​AESI surveillance 5 NA 5
​Cohort event monitoring
 952
 930
 22
Total 1,159 1,049 110

*AEFI, adverse events following immunization; AESI, adverse events of special interest; nOPV2, novel oral poliovirus vaccine type 2. †AEFI are defined as any untoward medical occurrence which follows immunization that does not necessarily have a causal relationship with the usage of the vaccine. ‡Two duplicates were identified from AFP surveillance (deduplicated total = 157) that were also identified through active hospital-based surveillance. §After investigation, 78 AFP cases were downgraded by the National AEFI Committee to nonserious cases.

Main Article

Page created: February 08, 2024
Page updated: March 20, 2024
Page reviewed: March 20, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external